Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy.

acute myeloid leukemia allogeneic stem cell transplantation anakoinosis biomodulatory treatment relapse

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 30 11 2019
accepted: 12 03 2020
entrez: 12 5 2020
pubmed: 12 5 2020
medline: 12 5 2020
Statut: epublish

Résumé

Early relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an often unsuccessful therapeutic challenge. Since treatment options are few and efficacy is low, new approaches such as

Identifiants

pubmed: 32391254
doi: 10.3389/fonc.2020.00443
pmc: PMC7190808
doi:

Types de publication

Case Reports

Langues

eng

Pagination

443

Informations de copyright

Copyright © 2020 Kattner, Holler, Herr, Reichle, Wolff and Heudobler.

Références

Leukemia. 2012 Mar;26(3):381-9
pubmed: 21886171
Biol Blood Marrow Transplant. 2010 Nov;16(11):1467-503
pubmed: 20699125
Curr Opin Hematol. 2002 Nov;9(6):503-8
pubmed: 12394172
Blood. 2008 Mar 1;111(5):2527-37
pubmed: 17965322
Eur J Cancer. 2017 Nov;86:233-239
pubmed: 29055209
Biol Blood Marrow Transplant. 2019 Apr;25(4):e128-e140
pubmed: 30658222
Arch Pathol Lab Med. 2010 Aug;134(8):1143-51
pubmed: 20670134
Blood. 2002 Sep 15;100(6):2132-7
pubmed: 12200377
Front Pharmacol. 2018 Nov 27;9:1380
pubmed: 30542286
Biol Blood Marrow Transplant. 2016 Jul;22(7):1324-1329
pubmed: 27026249
Haematologica. 2003 Jan;88(1):19-24
pubmed: 12551822
Leukemia. 2019 Feb;33(2):299-312
pubmed: 30651634
Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):556-62
pubmed: 26141213
Front Pharmacol. 2018 Nov 13;9:1279
pubmed: 30483125
Leuk Res. 2017 Dec;63:22-27
pubmed: 29096332
Blood. 2012 Feb 9;119(6):1599-606
pubmed: 22167752
Blood. 2001 Apr 15;97(8):2434-9
pubmed: 11290608
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Br J Haematol. 2001 Jun;113(4):983-8
pubmed: 11442493
Nat Med. 2018 Mar;24(3):282-291
pubmed: 29431743
Nat Commun. 2018 Jan 16;9(1):248
pubmed: 29339738
Blood. 2002 Jun 15;99(12):4326-35
pubmed: 12036858
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
Oncol Rev. 2012 Apr 17;6(1):e8
pubmed: 25992210
Haematologica. 2015 Jan;100(1):e4-6
pubmed: 25261094

Auteurs

Anna-Sophia Kattner (AS)

Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.

Ernst Holler (E)

Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.

Wolfgang Herr (W)

Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.

Albrecht Reichle (A)

Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.

Daniel Wolff (D)

Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.

Daniel Heudobler (D)

Department of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.

Classifications MeSH